Abstract

A COMPREHENSIVE REVIEW OF THE NOVEL DRUG FOR RESISTANT HYPERTENSION: APROCITENTAN

Naga Vinugna G. D.* and Dr. C. Renuka Thejeshwini

.

Abstract

Context: Resistant hypertension (RH) is associated with increased cardiovascular risk and unmet treatment needs due to neglected pathophysiologic pathways in guideline-recommended therapies. Although spironolactone is regarded as the recommended fourth-line treatment, its safety profile restricts its wide range of use. The FDA has approved a novel dual endothelin (et) A and B receptor antagonist called aprocitentan. Objective: The purpose of this study is to provide an overview of the data that is currently available about the discovery, pharmacokinetics, pharmacodynamics, safety, and effectiveness of aprocitentan in the treatment of RH. Methods: To find pertinent studies on the usage of aprocitentan, we explored PubMed, clinicaltrials.gov, and worldwide Pharmaceutical Abstracts. A search of clinical trial registries was also conducted. Conclusion: Aprocitentan is a revolutionary medicine for managing RH that significantly lowers blood pressure compared to placebo. It broadens our understanding of the pathophysiology of RH and offers promising opportunities for future treatment strategies. On the other hand, information about its long-term safety profile and wider cardiovascular and renal protection is lacking.

Keywords: Resistant Hypertension (RH), Aprocitentan, Endothelin Receptor Antagonist (ERA), Efficacy and Safety.